Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
edaravone + dextran
- Development stage
- Unknown
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Edaravone + dextran is an investigational polymer-drug conjugate consisting of the neuroprotective agent edaravone and the biocompatible polysaccharide dextran. Developed by researchers at The First Affiliated Hospital of Nanjing Medical University, this formulation is specifically designed for the treatment of acute ischemic stroke. Edaravone functions as a potent free radical scavenger, neutralizing reactive oxygen species (ROS) such as hydroxyl radicals to prevent oxidative damage to neurons and vascular endothelial cells during the ischemic cascade and subsequent reperfusion. The conjugation with dextran is intended to optimize the pharmacokinetic profile of edaravone, specifically by extending its short biological half-life and improving its solubility, which may lead to enhanced neuroprotective efficacy compared to standard edaravone therapy.
- Other names
- Edaravone-dextranEdaravone-dextran conjugate
Beyond the preview
Go deeper on edaravone + dextran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on edaravone + dextran.